PCR Perspectives

Howard Herrmann and Raj Makkar discuss valve under-expansion in the ACURATE neo2 from the IDE trial sub-study. Fluoroscopy showed about 22 % of valves were under-expanded, often linked to heavy calcium buildup. These valves had worse outcomes, including higher rates of death and stroke. What’s behind this issue, and how can it be prevented? Listen to their #europcr 2025 discussion to learn more! H...

Robert Byrne and Bruno Scheller discuss drug-coated balloon (DCB) angioplasty at #europcr 2025. Nearly 20 years after its introduction, where does DCB angioplasty stand today? When and how should it be used in daily practice? Discover what defines adequate lesion preparation for a DCB strategy in de novo disease, the role of intravascular imaging in deciding when to use DCB, and best practices for...

In this #europcr 2025 interview, Tanja Rudolph, Dan Blackman, and Radoslaw Parma explore the crucial aspects of repeat transcatheter valve replacement. They dive into the risks of coronary obstruction, the importance of preserving coronary access, and strategies to optimise hemodynamics despite higher residual gradients. The discussion also covers how the index TAVR device impacts outcomes and why...

Tiffany Patterson, Nicolas Van Mieghem, and Philippe Généreux reveal the hottest emerging TAVI indications for 2025 in this #europcr 2025 discussion. They review key trials on asymptomatic severe aortic stenosis—RECOVERY, AVATAR, ONLY TAVR, and EVoLVeD—which show early TAVI or surgery reduces hospitalisations for heart failure and suggests lower mortality and stroke compared to clinical surveillan...

When should TAVI be performed—and how should coronary disease be managed in these patients? Liesbeth Rosseel, Davide Capodanno, and Michael Joner explore two key questions shaping the future of TAVI. They highlight findings from the EARLY-TAVI trial, which shows that early intervention in asymptomatic patients with severe aortic stenosis significantly reduces rehospitalisation. Then, they turn to...

Simon Redwood interviews John Forrest, principal investigator of the Evolut Low Risk Bicuspid Study, during #europcr 2025. As TAVR moves into younger patients—many with bicuspid valves—questions remain about how well the procedure performs in this anatomy, which was excluded from earlier trials. In this exchange, they review the study design, patient selection, and main outcomes, and compare resul...

In this #europcr 2025 interview, Davide Capodanno and Woong Chol Kang explore the latest insights from the 4D-ACS trial and what it could mean for antithrombotic therapy in patients with acute coronary syndrome. They discuss who was included in the trial and walk through the two de-escalation strategies that were tested: reducing the number of the drugs, from dual antiplatelet therapy to single an...

What’s the best approach for STEMI patients with multivessel disease? Angela Mcinerney, Natalia Pinilla, and Matthias Götberg share their perspectives on how practice has evolved, with a focus on the COMPLETE trial and its intracoronary imaging substudy. They discuss what imaging reveals about non-culprit lesions, how it may influence treatment, and how these insights are applied in daily cathlab...

In this #europcr 2025 video, Nicola Ryan speaks with Dejan Milasinovic about when and how to adopt an upfront two-stent strategy in bifurcation PCI. The key is assessing the side branch: if stenosis is high-grade and disease is extensive, treatment may be needed from the start—using POBA, a DCB, or a second stent. Anatomy should guide the choice between a provisional or two-stent approach. Intraco...

In this #europcr 2025 discussion, Mayra Guerrero, Thomas Modine, and Philipp Lurz share their views on the evolving landscape of mitral valve treatment. While transcatheter edge-to-edge repair (TEER) remains a safe and effective approach, it doesn’t work for every patient. That’s why alternatives like TMVR, annuloplasty, or NeoChords—all currently under investigation—are generating attention. The...

Calcified bifurcation lesions remain one of the toughest challenges in interventional cardiology, combining two high-risk features into one complex scenario. In this #europcr 2025 interview, Dejan Milasinovic, Miroslaw Ferenc, and Mohamed Abdel Wahab explore why this topic deserves special attention. They break down how intra-coronary imaging can guide the approach, help tailor strategy, and ultim...

How effective is cerebral protection during TAVI? Bernard Prendergast and Rajesh Kharbanda take a deep dive into this key procedural question, reviewing the latest evidence from two major randomised trials—PROTECTED TAVR and BHF PROTECT-TAVI. Although both studies individually failed to demonstrate a clinical benefit for cerebral protection devices, a new patient-level meta-analysis presented at #...

In this exchange, Vijay Kunadian and Javier Escaned explore the real-world implementation of INOCA (Ischemia with Non-Obstructive Coronary Arteries) and ANOCA (Angina with Non-Obstructive Coronary Arteries) diagnostic pathways. Drawing on the 2024 CCS (Chronic Coronary Syndromes) guidelines, and the EAPCI consensus document, they discuss why these conditions remain underdiagnosed—and how structure...

At #EuroPCR2025, Martine Gilard, Antonio Mangieri, and Marco Barbanti share their perspectives on managing coronary artery disease in patients scheduled for TAVI. Is coronary angiography always necessary? When should PCI be performed—before, during, or after the procedure? And how do you decide? Tune in for a practical exchange on strategy, timing, and patient selection! Hosted on Acast. See acast...

Nicola Ryan and Flavio Ribichini discuss the challenges of treating the calcified left main stem. They break down the complexities of this high-risk condition and highlight the role of mechanical circulatory support in everyday practice. They focus on the role of intracoronary imaging as a game-changer and examine the use of one versus two stents, outlining cases where two stents may be necessary....

What does the PREVENT trial tell us about managing vulnerable plaques? Recorded during #europcr 2025, this discussion features Michael Haude and Thomas Cuisset as they review key insights from this major study of over 1,600 patients with physiologically non-significant but vulnerable plaques identified by intracoronary imaging—mainly IVUS. Patients were randomised to receive either optimal medical...

Stephan Windecker and Flavio Ribichini review the outcomes of the FAITAVI trial, presented during the #europcr 2025 LBT session. As coronary artery disease is the most common cardiac comorbidity in patients undergoing TAVI, the trial set out to evaluate whether physiology-guided decision-making could offer better clarity. When performing diagnostic angiography before TAVI, clinicians often find in...

Cleverson Zukowski and Pablo Lamelas take a moment during #europcr 2025 to shed light on a major regional milestone: the first-ever guidelines for the treatment of left main disease, issued jointly by the Latin American Society of Interventional Cardiology (SOLACI) and the Interamerican Society of Cardiology (SIAC). Why were these guidelines created specifically for Latin America? What are their k...

In this #europcr 2025 exchange, Ole De Backer and Philippe Garot explore the evolving landscape of transcatheter left atrial appendage (LAA) occlusion. From differences in patient selection on either side of the Atlantic—high bleeding risk in Europe vs. broader indications in the US—to upcoming pivotal trials comparing LAA closure to DOACs, this conversation covers it all. They also break down wha...

Elliot Smith, Thomas Hovasse, and Roberto Garbo present a structured, step-by-step approach to chronic total occlusion (CTO) interventions, starting from angiographic analysis through to strategy selection and technique adaptation. The discussion begins with angiographic assessment, emphasising the importance of identifying key anatomical features upfront. Based on this evaluation, operators deter...

What is the optimal TAVI access approach in today’s practice? In this conversation at PCR London Valves 2024, Ole De Backer and Maarten Vanhaverbeke break down the latest evidence and trends in TAVI access. Listen to this podcast to learn about the dominance of transfemoral access, the role of alternative routes like transcarotid and transaxillary, the growing use of cutting-edge tools like intrav...

How do we navigate the thin line between bleeding risk and thrombosis in high-risk patients undergoing tricuspid valve interventions? Marianna Adamo and Fabien Praz explore the latest strategies in anticoagulation, the challenges of managing complex cases and how cutting-edge research is shaping the future of care. Listen to this podcast to discover the keys to optimizing outcomes in this rapidly...

Curious about the specific considerations for TAVI in women? Martine Gilard and Dan Blackman highlight the challenges women face in the diagnosis and treatment of aortic stenosis (underrepresentation, later presentation, undertreatment...) while exploring key anatomical differences (smaller aortic anatomy, less calcification...), and how these factors impact diagnostic thresholds, imaging and valv...

Wondering which is the better option for female patients—SAVR or TAVR? Don’t miss this exchange between Hendrik Treede and Hélène Eltchaninoff. They explore the unique challenges and nuances of valve interventions for women, highlighting evolving strategies to optimize treatment and improve outcomes. Hosted on Acast. See acast.com/privacy for more information.

Curious about the latest advancements in transcatheter tricuspid valve interventions? Don't miss this discussion between Philipp Lurz and Lukas Stolz at PCR London Valves 2024! They delve into the topic of residual tricuspid regurgitation after transcatheter repair—a challenge that still needs improvement despite significant progress. Hosted on Acast. See acast.com/privacy for more information.